Advancements in Cell and Gene Therapies

A #Breakthrough Year for T Cells This year has been transformative for T cell therapies in the fight against cancer, as reviewed by Rigel Kishton and me in today’s issue of Nature Cancer (https://rdcu.be/d3R8D). With three FDA approvals, 2024 has underscored the clinical power of #Tcells -- living #immunotherapies capable of achieving results where all other treatments fail. Key Approvals of 2024 -> #Lifileucel (Amtagvi): The first #TIL-based therapy for unresectable/metastatic melanoma, approved in February. -> Afamitresgene (Tecelra): The first #TCR-engineered therapy for solid tumors, approved in August for synovial sarcoma. -> Obecabtagene (Aucatzyl): The 7th #CAR T therapy for B cell hematologic malignancies, approved last month. 🚀 These therapies are clinically remarkable. Engineered from a patient’s own T cells, they deliver life-changing responses for patients with no other options. I’ve had the privilege of contributing to these advancements and witnessing their profound impact. The Promise of TIL Therapies TIL-based therapies hold transformative potential. By recognizing tumor #neoantigens -- expressed #mutations, cancer germline antigens, and even “#darkgenome” products like #HERVs or #pseudogenes -- T cells can achieve durable, complete responses. CD4+ and CD8+ T cells bring the ability to directly or indirectly eliminate tumors where traditional therapies fall short. Despite these advances, the oncology capital markets remain skeptical. Cell therapy companies face immense challenges: -> Development Costs: Complex manufacturing, high trial expenses, and stringent regulations. -> Safety Concerns: Risks like cytokine release syndrome and lymphodepletion-associated toxicities. -> Commercialization Hurdles: High prices, uncertain reimbursement, and cumbersome logistics. The result? T cell-based immunotherapies can land with a thud from investors concerned about small target markets and costly treatment delivery. ⚡ Technology as a Solution The future of T cell-based therapies looks brighter with technological innovation: -> #AI/ML for Transcriptomics and Genomics: Personalizing T cell products for individual patients. -> Cheaper #Sequencing: Accelerating tumor neoantigen target discovery. -> Improved Culture Methods: Enhancing T cell #stem cell qualities for durable efficacy. While #Tcellengagers and #bispecificantibodies gain investor interest for their transient solid tumor activity, these treatments are rarely curative. TIL therapies, on the other hand, stand on the cusp of delivering transformative, long-term responses in patients with common solid tumors. The journey isn’t easy—financial skepticism, logistical hurdles, and scientific complexity remain—but the horizon for T cell therapies is filled with extraordinary possibility. Here’s to the progress we've made and the breakthroughs that lie ahead. 🎇 #immunotherapy #celltherapy #carT #TIL #oncology

Autologous vs. Allogeneic: A Paradigm Shift in Clinical Impact While autologous cell therapies (patient-specific) have demonstrated remarkable efficacy (90%+ in indications like B-cell malignancies), their limitations are increasingly untenable: weeks-long manufacturing delays, 10–15% production failures, and costs exceeding $500K. These bottlenecks restrict patient access, particularly in rapidly progressing diseases or resource-limited settings. 2025: The Allogeneic Tipping Point Next-generation allogeneic "off-the-shelf" therapies are poised to dominate the cell therapy landscape, driven by three transformative advancements: 1) Immune Evasion Breakthroughs: CRISPR-Cas9 and base-editing technologies (e.g., Beam Therapeutics’ cytosine base editing) enable precise disruption of HLA and TCR genes, reducing immune rejection risks. Clinical data from Allogene Therapeutics’ ALPHA2 trial (NCT04416984) show 76% objective response rates in relapsed/refractory lymphoma, mirroring autologous CAR-T outcomes. 2) Elimination of GvHD: Tools like TALEN-edited cells (Cellectis’ UCART19) report 0% Grade 3–4 GvHD in pediatric B-ALL patients (NCT02808442), with durability extending to 24+ months. 3) Scalable Manufacturing: Automated closed-system bioreactors (Lonza’s Cocoon®) and master cell banks reduce batch variability by 85% and costs by ~60% (per-dose estimates: 150K vs. 150 K vs. 400K for autologous). - Recent trials underscore allogeneic therapies’ expanding utility: 1) Solid Tumors: CRISPR Therapeutics’ CTX110 (anti-CD19 allogeneic CAR-T) achieved 57% CR rates in CD19+ B-cell malignancies (Phase 1, ASH 2022). 2) Autoimmune Diseases: Cabaletta Bio’s DSG3-CAART (for pemphigus vulgaris) eliminated pathogenic antibodies in 100% of Phase 1 patients (NCT04422912). 3) Acute Indications: Atara Biotherapeutics’ tabelecleucel (off-the-shelf EBV T-cell therapy) delivered 50% 1-year survival in post-transplant lymphoproliferative disorder (PTLD), addressing urgent unmet needs. - Market Landscape: A $23.6B Opportunity by 2030, fueled by: 1) Pipeline Expansion: 250+ allogeneic candidates in clinical trials (60% in oncology, 25% in autoimmune diseases). 2) Regulatory Tailwinds: FDA RMAT designation granted to 15 allogeneic programs (e.g., Precision Biosciences’ PBCAR0191), accelerating pathways to approval. 3) The ability to treat 10–100x more patients per batch vs. autologous therapies creates a winner-takes-most market dynamic. Don’t wait for the market to mature—dominate the inflection point. What are your thoughts? I read you in the comments ____________________________________________________________________________ 🔔 Follow for insights ♻️ Share if you find it interesting #celltherapy #biotech #investment #investor

Imagine gene therapy treatments costing $100,000 instead of $2 million per dose. A new review shows this isn't just wishful thinking – continuous bioprocessing could reduce manufacturing costs by up to 80%, potentially transforming patient access to these life-changing treatments. A exciting review paper by Lorek et al. reveals how the shift from traditional batch processing to continuous manufacturing may revolutionize gene therapy production. The innovation lies in running multiple production steps simultaneously with constant material flow, enabled by multi-column chromatography systems and advanced process analytic technology (PAT). What makes this particularly exciting is how continuous processing addresses the core challenges of gene therapy manufacturing. Traditional batch processing requires larger facilities, faces significant downtime between batches, and struggles with consistency. In contrast, continuous processing achieves higher productivity at a smaller scale while improving product quality – critical factors for reducing those astronomical million-dollar-plus treatment costs. The technology behind this transformation is fascinating. Multi-column chromatography systems now enable continuous capture and purification of viral vectors, improving productivity nearly threefold while maintaining yields above 82%. Even more impressive is the integration of real-time monitoring through process analytical technologies. These systems use in -line spectroscopic sensors, dynamic light scattering, and rapid analytics to track critical quality attributes in real-time, ensuring consistent product quality while dramatically reducing manufacturing time and costs. The implications for patient care are profound. By reducing facility footprint, increasing productivity, and improving product quality, continuous processing could help transform gene therapies from last-resort options into more widely accessible treatments. Early studies suggest manufacturing costs could drop by 60-80% compared to traditional batch processing – a game-changing reduction that could dramatically expand patient access. What excites me most is how these advances are converging with artificial intelligence and automation. Real-time monitoring systems coupled with advanced process controls are enabling unprecedented precision in manufacturing, ensuring every batch meets the highest quality standards while maximizing efficiency. We're witnessing a fundamental shift in how gene therapies are manufactured. The question isn't just about cost reduction – it's about reimagining production to make these transformative treatments accessible to everyone who needs them. What are your thoughts on these developments? How do you see these manufacturing innovations reshaping the future of genetic medicine? #GeneTherapy #Biotechnology #ContinuousProcessing #Healthcare #Innovation #PatientAccess

Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of hematologic malignancies, achieving remarkable clinical success with FDA-approved therapies targeting CD19 and BCMA. However, the extension of these successes to solid tumors remains limited due to several intrinsic challenges, including antigen heterogeneity and immunosuppressive tumor microenvironments. In this review, we provide a comprehensive overview of recent advances in CAR T cell therapy aimed at overcoming these obstacles. We discuss the importance of antigen identification by emphasizing the identification of tumor-specific and tumor-associated antigens and the development of CAR T therapies targeting these antigens. Furthermore, we highlight key structural innovations, including cytokine-armored CARs, protease-regulated CARs, and CARs engineered with chemokine receptors, to enhance tumor infiltration and activity within the immunosuppressive microenvironment. Additionally, novel manufacturing approaches, such as the Sleeping Beauty transposon system, mRNA-based CAR transfection, and in vivo CAR T cell production, are discussed as scalable solution to improve the accessibility of CAR T cell therapies. Finally, we address critical therapeutic limitations, including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and suboptimal persistence of CAR T cells. An examination of emerging strategies for countering these limitations reveals that CRISPR-Cas9-mediated genetic modifications and combination therapies utilizing checkpoint inhibitors can improve CAR T cell functionality and durability. By integrating insights from preclinical models, clinical trials, and innovative engineering approaches, this review addresses advances in CAR T cell therapies and their performance in solid tumors. https://lnkd.in/edX-9SbP

𝗖𝗲𝗹𝗹 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 𝗶𝗻 𝟮𝟬𝟮𝟰: 𝗔 𝗬𝗲𝗮𝗿 𝗼𝗳 𝗨𝗻𝗽𝗿𝗲𝗰𝗲𝗱𝗲𝗻𝘁𝗲𝗱 𝗚𝗿𝗼𝘄𝘁𝗵 𝗮𝗻𝗱 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 2024 has been a transformative year for cell therapy, marked by groundbreaking advancements, key regulatory approvals, and significant market growth. This momentum highlights the sector’s potential to deliver life-changing treatments for some of the world’s most challenging diseases. Regulatory Milestones - This year has seen several major FDA approvals that demonstrate the progress and diversity of cell therapy applications. These approvals underscore the field’s ability to bring innovative therapies from the lab to the clinic. • Casgevy (exagamglogene autotemcel): The first CRISPR/Cas9-based gene therapy, approved in January for sickle cell disease. • Amtagvi (lifileucel): Approved in February as a T cell immunotherapy for metastatic melanoma. • Tecelra (afamitresgene autoleucel): Accelerated approval in August for synovial sarcoma, advancing TCR gene therapies. • Breyanzi (lisocabtagene maraleucel): Expanded approval in May for relapsed or refractory follicular lymphoma. Market Expansion and Investment - The cell therapy market is projected to grow to over $48 billion by 2027, with a compounded annual growth rate of nearly 16%. Investor enthusiasm remains high, as funding in 2024 has already surpassed 2023 levels, according to the Alliance for Regenerative Medicine. Key developments include: • 795 active clinical trials, including 98 in Phase III, addressing cancer, genetic diseases, cardiovascular conditions, and more. • Late-stage programs from companies like Vertex Pharmaceuticals, Capricor Therapeutics, and Mesoblast, with potential approvals in 2025. Challenges and Opportunities - While the progress is remarkable, the sector still faces hurdles: • High manufacturing costs and scalability challenges, particularly for autologous therapies. • Complex regulatory frameworks that must adapt to evolving technologies. However, the collective efforts of developers, investors, and regulatory bodies are helping to address these issues, paving the way for broader access to these transformative treatments. Looking Ahead - With a strong pipeline of trials, increased global investment, and continuous innovation, cell therapy is positioned to redefine medicine and improve patient outcomes on a global scale. The breakthroughs of 2024 are just the beginning of what’s to come for this transformative field.

🚀 New publication alert! 🚀 Excited to share our latest work published in Nature Communications: "Unlocking the potential of engineered immune cell therapy for solid tumors" Adoptive cell therapy (ACT) has revolutionized the treatment landscape of hematologic malignancies, but solid tumors remain a formidable challenge. In this piece, we explore how genetic engineering strategies—ranging from immune checkpoint silencing to metabolic reprogramming—are paving the way for more effective and durable immune cell therapies in solid tumors. 💡 Key takeaways: ✅ Advances in TIL, CAR-T, and TCR-T therapies are expanding treatment options. ✅ Genetic editing techniques (e.g., CRISPR) can enhance T-cell persistence and function. ✅ Armored T cells and metabolic reprogramming hold promise for overcoming the tumor microenvironment. ✅ Beyond T cells, the future lies in engineered macrophage and NK cell therapies, as well as allogeneic ‘off-the-shelf’ solutions. Link: https://lnkd.in/dSVkgD5Q A huge thank you to Víctor Albarrán Fernández, who led this Comment, Laura Angelats, Julio Delgado, Alena Gros Vidal, Álvaro Urbano-Ispizua, and Sonia Guedan #ClinicBCNCancerCenter Hospital Clínic de Barcelona Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Universitat de Barcelona

🚀 A Step Closer to In Vivo CAR T Therapies CAR T cells have transformed cancer treatment, offering curative potential for B cell malignancies. Yet, their widespread use is limited by complex manufacturing and high costs. What if instead of engineering T cells outside the body, we could generate them inside the patient? A new study - “Efficient in vivo generation of CAR T cells using a retargeted fourth-generation lentiviral vector” by Tiziana Coradin and colleagues, published in Cell Press - explores exactly that, developing fourth-generation lentiviral vectors (LVs) engineered with Nipah virus-derived “mixed” envelopes to deliver CAR transgenes directly to T cells in vivo. 📌 Key innovations: 1. Targeted envelopes. Using DARPins and VHH binders to specifically direct LVs to CD3+ or CD8+ T cells. 2. Mixed envelope strategy. Combining retargeted and non-targeted proteins boosted transduction efficiency. 3. Enhanced safety. The SupA2KO-LV backbone with TRiP system minimized aberrant RNA splicing and prevented CAR protein incorporation into viral particles. 4. In vivo efficacy. In humanized mouse models, systemic injection led to rapid generation of functional CAR T cells, sustained expansion, and efficient B cell ablation. The results show that direct in vivo CAR T cell generation is not only possible but highly efficient. If translated clinically, this approach could overcome major hurdles of cost, scalability, and patient access that limit current CAR T therapies. This work is an exciting step toward democratizing CAR T therapy and making next-generation cell therapies accessible on a global scale. 💬 What do you see as the greatest challenge in translating in vivo CAR T therapies from preclinical models to human patients? Read full article: https://lnkd.in/eh_uTShF #CellTherapy #CART #GeneTherapy #Biotechnology #Oncology

Most cell therapies hinge on gene editing. But how exactly are scientists revising the blueprint of life to unleash the potential of cells to fight diseases? Welcome to Week 10 of my Cell and Gene Therapy series, where we'll explore both 𝘃𝗶𝗿𝗮𝗹 and 𝗻𝗼𝗻-𝘃𝗶𝗿𝗮𝗹 𝗴𝗲𝗻𝗲 𝗲𝗱𝗶𝘁𝗶𝗻𝗴 approaches to cell therapy. Nature has endowed some 𝘃𝗶𝗿𝘂𝘀𝗲𝘀 with the unique ability of sneaking into our cells so they can 𝘀𝗹𝗶𝗽 𝘁𝗵𝗲𝗶𝗿 𝗴𝗲𝗻𝗲𝘁𝗶𝗰 𝗺𝗮𝘁𝗲𝗿𝗶𝗮𝗹 𝗶𝗻𝘁𝗼 𝗼𝘂𝗿 𝗗𝗡𝗔 with remarkable efficiency. But scientists have repurposed these viruses to act as 𝗰𝗮𝗿𝗿𝗶𝗲𝗿𝘀 (𝘃𝗲𝗰𝘁𝗼𝗿𝘀) to deliver therapeutic genes that can be inserted into our DNA. All six FDA-approved autologous CAR-T therapies use 𝘃𝗶𝗿𝗮𝗹 𝘃𝗲𝗰𝘁𝗼𝗿𝘀 to furnish T cells with anti-cancer modules (e.g., CAR): - Novartis's Kymriah (2017): lentiviral vector - Kite Pharma's Yescarta (2017) and Tecartus (2020): retroviral vector - Bristol Myers Squibb's Breyanzi (2021) & Abecma (2021): lentiviral vector - Janssen Inc.'s Carvykti (2022): lentiviral vector In addition, bluebird bio’s Lyfgenia (2023) uses a replication-incompetent, self-inactivating lentiviral vector to add functional copies of the hemoglobin gene into stem cells. While widely utilized due to its 𝗲𝗳𝗳𝗶𝗰𝗶𝗲𝗻𝗰𝘆 and 𝗽𝗿𝗼𝘃𝗲𝗻 𝘀𝘂𝗰𝗰𝗲𝘀𝘀, viral vectors come with notable limitations. Chief among these are: 1) the risk of 𝗿𝗮𝗻𝗱𝗼𝗺 𝗶𝗻𝘀𝗲𝗿𝘁𝗶𝗼𝗻, which could disrupt crucial genes in host cells, potentially leading to adverse effects, such as cancers; and 2) the 𝗰𝗼𝗺𝗽𝗹𝗲𝘅𝗶𝘁𝘆 𝗮𝗻𝗱 𝗵𝗶𝗴𝗵 𝗰𝗼𝘀𝘁𝘀 associated with producing viral vectors meeting necessary standards of quality and consistency. Non-viral gene editing approaches, on the other hand, transport genetic material into cells 𝘄𝗶𝘁𝗵𝗼𝘂𝘁 𝘁𝗵𝗲 𝗮𝗶𝗱 𝗼𝗳 𝘃𝗶𝗿𝘂𝘀𝗲𝘀. 𝗘𝗹𝗲𝗰𝘁𝗿𝗼𝗽𝗼𝗿𝗮𝘁𝗶𝗼𝗻 is the most popular way to deliver genetic material without viruses. It works by sending a current through cells, 𝘁𝗲𝗺𝗽𝗼𝗿𝗮𝗿𝗶𝗹𝘆 𝗼𝗽𝗲𝗻𝗶𝗻𝗴 𝗽𝗼𝗿𝗲𝘀 in the cell membrane. Many major gene editing platforms are compatible with electroporation, including CRISPR/cas9, zinc-finger, TALENs, and transposon systems. Notably, Vertex Pharmaceuticals’s CASGEVY (2023) treats sickle cell disease with genetically modified stem cells. A 𝗽𝗿𝗲𝗰𝗶𝘀𝗲 𝗺𝗼𝗱𝗶𝗳𝗶𝗰𝗮𝘁𝗶𝗼𝗻 at the enhancer region of 𝘉𝘊𝘓11𝘈 gene is achieved via CRISPR/Cas9 technology with electroporation. As electroporation becomes more widely used, a few key considerations remain: 1) the ability to 𝗳𝗶𝗻𝗲-𝘁𝘂𝗻𝗲 and optimize the electric current parameters for specific cell types and genome editing tools; 2) 𝗹𝗶𝗰𝗲𝗻𝘀𝗶𝗻𝗴 𝗳𝗲𝗲𝘀 and 𝗿𝗼𝘆𝗮𝗹𝘁𝘆 structures; and 3) the ability to maintain a fully 𝗰𝗹𝗼𝘀𝗲𝗱 𝘀𝘆𝘀𝘁𝗲𝗺 to ensure sterility and prevent contamination. What are your thoughts on the evolution of gene editing technologies in cell therapy? Share your insights or questions below!

🚀 A Big Moment for Cell, Gene & RNA Therapies! Amid a challenging few years for biotech, it’s encouraging to see multiple late-stage cell, gene, and RNA therapies approaching meaningful readouts. According to recent industry coverage, four major programs in H1 2026 alone underscore growing momentum across gene therapy, gene editing, and RNA-based medicines. Why this matters 👇 ✔ Patients could gain access to potentially transformative treatments for serious and underserved diseases ✔ The industry continues to validate advanced modalities beyond traditional small molecules ✔ Investors are seeing clearer late-stage signals after years of heavy R&D investment 🔬 Programs to watch: • Regenxbio – RGX-202 A next-generation AAV gene therapy for Duchenne muscular dystrophy designed to deliver a more functional microdystrophin protein. • Intellia Therapeutics – lonvo-z A CRISPR-based gene editing therapy for hereditary angioedema that could offer a functional cure with a single treatment. • Novartis – pelacarsen (Lp(a) Horizon) An RNA antisense therapy targeting lipoprotein(a), a genetically driven cardiovascular risk factor with no approved treatments today. • Sarepta Therapeutics / Arrowhead Pharmaceuticals – SRP-1001 & SRP-1003 RNA interference (RNAi) therapies aimed at neuromuscular diseases, representing a potential lifeline for Sarepta and a broader validation of RNAi in muscle disorders. 📈 The takeaway: These programs highlight a critical shift — advanced genetic medicines are no longer just scientific breakthroughs, they’re entering pivotal stages where clinical impact, regulatory clarity, and commercial viability come into focus. For patients, that means hope. For the industry, resilience. For investors, renewed confidence in long-term innovation. #Biotech #GeneTherapy #CellTherapy #RNA #LifeSciences https://lnkd.in/eJm6Xd9x